Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

101 results about "Discontinuation" patented technology

Medication discontinuation is the ceasing of a medication treatment for a patient by either the clinician or the patient themself. When initiated by the clinician, it is known as deprescribing. Unlike the prescribing of medications, appropriate discontinuation has not attracted nearly as much attention or interest.

Methods of using fuel cell system configured to provide power to one or more loads

A fuel cell system is described for providing primary and/or auxiliary/backup power to one or more loads selected from the group comprising: lawn & garden equipment; radios; telephone; targeting equipment; battery rechargers; laptops; communications devices; sensors; night vision equipment; camping equipment; stoves; lanterns; lights; vehicles; cars; recreational vehicles; trucks; boats; ferries; motorcycles; motorized scooters; forklifts; golf carts; lawnmowers; industrial carts; passenger carts (airport); luggage handling equipment (airports); airplanes; lighter than air crafts; blimps; dirigibles; hovercrafts; trains; locomotives; submarines (manned and unmanned); torpedoes; security systems; electrical energy storage devices for solar-based, tidal-based, hydro-based, wind-based, and other renewable energy source; equipment for which a primary and/or backup power source is necessary or desirable to enable the equipment to function for its intended purpose, military-usable variants of above, and suitable combinations of any two or more thereof. The system provides power to the one or more loads upon the occurrence of a power outage condition, which includes a disruption or discontinuation in the delivery of primary power (i.e., power from a system-external primary source, namely, a source other than the fuel cell system) to, or power demand condition by, the one or more loads. A controller senses outage of primary power to, or demand for primary power by, the one or more loads, and, responsive thereto, operatively engages one or more fuel cells to provide power to the one or more loads.
Owner:METALLIC POWER INC

Combinations of HMG-COA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night

The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixtures thereof, and (3) a swelling agent to form a sustained release composition for extended release of the nicotinic acid or nicotinic acid compound or mixtures thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a composition for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl methylcellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an HMG-CoA reductase inhibitor in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compounds to provoke flushing reactions in individuals.
Owner:KOS LIFE SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products